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Rhabdomyosarcoma is a highly malignant soft-tissue sarcoma that
occurs primarily in childhood. It accounts for 6–7% of all cancers
in children and over half of all paediatric soft-tissue sarcomas
(Enzinger and Weiss, 1995). It is classified according to histology
and the two major classifications in paediatric cases are alveolar
and embryonal (Enzinger and Weiss, 1983). The alveolar form
usually has a specific chromosomal t(2;13)(q35;q14) translocation
which gives rise to a novel fusion protein (Douglass et al, 1987).
The presence of this translocation correlates with a worse
prognosis and treatment is therefore adjusted accordingly.
Drugs commonly used for treatment include vinca alkaloids,
anthracyclines, etoposide and cyclophosphamide.
The long-term survival rate for paediatric rhabdomyosarcoma is
now approximately 70%, compared to 20% in 1970 (Pappo et al,
1995). This recent improvement is largely due to the use of more
effective multi-agent chemotherapy. Despite this, relapse due to
drug resistance remains a major obstacle to survival. It has become
apparent in recent years that multidrug resistance (MDR) may be
one of the main reasons for this. In rhabdomyosarcoma, an associ-
ation between the presence of P-glycoprotein (P-gp, encoded by
the gene mdr-1) and adverse prognosis has been documented
(Chan et al, 1990) but more recent studies have failed to confirm
this (Kuttesch et al, 1996). More recently, other mechanisms such
as multidrug resistance-related protein (MRP) (Cole et al, 1992)
and lung cancer resistance protein (LRP) (Scheper et al, 1993)
have also been implicated in the MDR phenotype, although not
specifically in rhabdomyosarcoma. LRP sequesters drugs thereby
reducing their availability in the cell. P-gp and MRP efflux a
variety of drugs used to treat cancer, thereby reducing the
availability of drug at the target and reducing the effectiveness of
treatment.
Ways of reversing or modulating multidrug resistance have
been researched extensively in recent years and several
compounds have been found which affect the MDR mechanisms
(reviewed by Ford, 1996). These include the immunosuppressive
cyclosporin A and the calcium channel-blocker verapamil. The
effectiveness of these agents in rhabdomyosarcoma in vitro has
been investigated (Cowie et al, 1998). However, the use of these
agents as MDR modulators in vivo is limited by toxicity due to
side-effects such as nephrotoxicity for cyclosporin A and cardiac
toxicity for verapamil.
Currently one of the most promising MDR modulators is the
non-immunosuppressive cyclosporin A analogue, PSC833, which
is specific for P-gp (Naito and Tsuruo, 1997). This is currently
undergoing phase III clinical trials in relapsed acute myeloid
leukaemia and in relapsed or refractory multiple myeloma. The
compound has also undergone several phase I and II trials in
various types of cancer. Another compound is the novel modulator
VX710 (Germann et al, 1997a), a non-macrocyclic pipecolinate
derivative which binds the FK506 receptor protein. It inhibits the
efflux activity of P-glycoprotein and stimulates vanadate sensitive
P-glycoprotein ATPase activity, suggesting a direct high-affinity
interaction between VX710 and P-glycoprotein (Germann et al,
1997a). VX710 has also been shown to modulate MRP-mediated
multidrug resistance, possibly by direct interaction (Germann et al,
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1997b). This agent is currently in phase II clinical trials in breast
cancer, ovarian cancer, soft-tissue sarcoma, liver cancer and
prostate cancer.
MDM2 protein binds and inactivates the tumour suppressor
protein p53 (Lane, 1992) and has recently been implicated in the
development of drug resistance (Kondo et al, 1996). It is known
that mdm2 is often overexpressed in sarcomas and in particular in
rhabdomyosarcoma (Keleti et al, 1996). The study also showed
that when mdm2 expression was normal, the tumour suppressor
gene, p53, was often mutant. Separate studies have shown that p53
mutations are often present in childhood rhabdomyosarcomas,
particularly at relapse (Felix et al, 1992; Wurl et al 1996).
In the present study a panel of seven paediatric rhabdomyosar-
coma cell lines have been characterized with regard to p53, p21
and mdm2 in addition to drug resistance phenotype and sensitivity
to the commonly used anti-cancer drugs, cisplatin, doxorubicin,
etoposide and vincristine. The ability of two different drug resis-
tance modulators to improve sensitivity has also been investigated.
MATERIALS AND METHODS
Cell lines
The panel of rhabdomyosarcoma cell lines is summarized in Table
1. Rh18, Rh30 and Rh36 were gifts from Dr PJ Houghton (St
Judes Children’s Research Hospital). SCMC was a gift from T
Sawada (Kyoto Prefectural University of Medicine, Japan). RMS
and RD were obtained from the American Tissue Culture
Collection (Rockville, Maryland, USA). All the rhabdomyo-
sarcoma lines used are negative for EWS-FLI-1 (Dr A Gordon,
personal communication). The lines Rh18, Rh30 and RMS have
the PAX3-FKHR translocation associated with t(2;13)(q35;q14)
and the line SCMC has a t(9;13) translocation, which does
not affect the FKHR gene, in addition to a cryptic
der(13)t(2;13)(q35;q14) translocation (Dr A Gordon, personal
communication).
The human ovarian carcinoma cell line CH1 and its multidrug
resistant variant CHIDoxR were used as negative and positive
controls for P-glycoprotein expression and function (Sharp et al,
1994). The human non-small cell lung carcinoma cell line
CORL23 and its multidrug resistant variant CORL23/R were used
as negative and positive controls for MRP expression (Barrand et
al, 1994). The non-small cell lung cancer cell line 2R120 and the
breast cancer cell line MCF-7 were used as positive and negative
controls respectively for LRP expression (Scheper et al, 1993).
The ovarian cell line A2780 was used as a wild-type p53 control
(Pestell et al, 1998).
All cell lines were maintained in RPMI 1640 medium (Sigma,
Poole, Hants, UK) supplemented with 10% foetal bovine serum
(Life Technologies, Scotland, UK) and 2 mM L-glutamine
(Sigma). Cells were grown as attached monolayers and were incu-
bated at 37°C in a humidified atmosphere with 5% CO2. All cell
lines were routinely screened for Mycoplasma by PCR assay
(Stratagene, Cambridge, UK).
Drugs and chemicals
Vincristine (David Bull Laboratories) and etoposide (Bristol
Myers Squibb Pharmaceuticals) stock solutions were obtained as
pharmacy preparations at concentrations of 1.083 mM and 34 mM
respectively. Doxorubicin (Sigma) was dissolved in water to give a
stock solution of 1 mM. Cisplatin (Johnson Matthey Technology
Centre, Reading, UK) was dissolved in 0.9% saline to give a stock
solution of 1 mM. VX710 (Vertex Pharmaceuticals Inc,
Cambridge, MA, USA) was dissolved in saline to give a 50 mM
stock solution. Finally, PSC833 (Sandoz Pharmaceuticals,
Camberley, UK) was dissolved in absolute ethanol to give a 1 mM
stock. All of these drugs were stored at –20°C with the exception
of vincristine which was stored at 4°C. Immediately prior to use
the drugs were diluted using RPMI 1640 medium prepared as for
cell culture, with the exception of vincristine which was diluted in
RPMI 1640 medium without any supplements.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (Sigma) was dissolved in PBS to produce a stock
solution of 5 mg ml–1 which was stored at 4°C.
Immunoblotting
Exponentially growing cells were harvested by trypsinization,
washed in PBS then incubated in 200–300 ml of lysis buffer
(pH 7.5, 150 mM NaCl, 50 mM Tris-HCl, 1 mM phenylmethyl-
sulphonyl fluoride (PMSF), 2 mg ml–1 aprotinin, 2 mg ml–1
leupeptin, 1 mM sodium orthovanadate, 1% NP40 and 0.2%
sodium dodecyl sulphate (SDS) at 4°C for 1 h. Cells were then
centrifuged at 7000 g (MSE Microcentrifuge) at 4°C for 15 min.
The protein-containing supernatant was collected and stored at
–70°C.
When immunoblotting for P-glycoprotein a membrane protein
preparation from the cells was used. Cells were harvested by
trypsinization, washed with PBS then lysed in 1 mM Tris (pH 7.4)
Table 1 Rhabdomyosarcoma cell line panel
Cell line Histological subtype Prior patient treatment Reference
Rh18 Mixed Untreated Houghton et al, 1982
Rh30 Alveolar Untreated Douglass et al, 1987
Rh36 Embryonal Multiagent chemotherapy Keleti et al, 1996
SCMC Alveolar Multiagent chemotherapya Hayashi et al, 1990
HX170 Embryonal Multiagent chemotherapyb Kelland et al, 1989
and radiotherapy
RMS Alveolar Multiagent chemotherapyc Garvin et al, 1986
RD Embryonal Cyclophosphamide and McAllister et al, 1969
radiotherapy
aVincristine, cyclophosphamide, doxorubicin and dactinomycin; bvincristine, cyclophosphamide and doxorubicin;
cvincristine, cyclophosphamide and actinomycin D340 HA Cocker et al
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containing 100 mg ml–1 PMSF at 4°C for 1 h. Nuclei and unbroken
cells were removed by centrifugation (450 g, 10 min, 4°C). The
resulting supernatant was centrifuged (60 000 g, 1 h, 4°C) to pellet
the cell membranes. The membrane proteins were resuspended in
lysis buffer and stored at –70°C.
The protein content of the samples was determined using a BCA
assay kit (Pierce, Rockford, IL, USA). Cell lysates were then diluted
1:1 in 2´ Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 20% (v/v)
glycerol, 10% (v/v) b-mercaptoethanol, 5% (w/v) SDS, 0.005%
(w/v) bromophenol blue) and denatured for 3 min at 95°C. Proteins
were resolved by electrophoresis down an 8–16% SDS-PAGE
gradient gel as previously described (Sharp et al, 1995). When
immunoblotting for P-gp or MRP, a 6% gel was used, to ensure
better separation of the protein of interest. Equal amounts of protein
from each sample were loaded into each well, typically 60 mg.
Proteins were then electroblotted onto a nitrocellulose filter
(Millipore) (Towbin et al, 1979) in a transfer buffer containing
10% methanol at 300 mA for 2 h at 4°C. Even loading and transfer
of proteins was assessed by staining with Ponceau S. The nitro-
cellulose filter was then blocked overnight in PBS (pH 7.6)
containing 0.5% casein. Target proteins were detected using a
primary antibody and an appropriate horseradish peroxidase-
labelled secondary antibody followed by enhanced chemilumines-
cence reagents (Amersham). Exposure of the nitrocellulose filter
to film (Hyperfilm-ECL, Amersham) was used to visualize protein
bands. The antibodies used were C219 (Centocor, USA) to detect
P-gp, MRPm6 (Monosan, Netherlands) to detect MRP, IF-2
(Oncogene, Cambridge, MA, USA) to detect MDM2, C19 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) to detect p21, DO-1
(Santa Cruz Biotechnology) to detect p53 and B-1-5-2 (Sigma) to
detect a-tubulin.
Immunohistochemistry
Cytospin preparations of approximately 50 000 cells were fixed in
acetone (for MRP and LRP) or 4% paraformaldehyde (P-gp) for
5 min, air-dried and pre-incubated in 10% rabbit serum in TBS.
This was followed by incubation with primary antibody for 1 h.
The antibodies used were MRK 16 (TCS Biologicals, Botolph
Claydon) diluted 1:50 to detect P-gp, MRPm6 diluted 1:100 to
detect MRP and LRP 56 (TCS Biologicals) diluted 1:20 to detect
LRP. All antibodies were titrated to ensure maximum sensitivity.
Incubation with the primary antibody was followed by incubation
for 30 min with rabbit anti-mouse antibody (Dako, Glastrup,
Denmark) diluted 1:50. A standard APAAP technique (Dako) was
used for colourimetric development with levamisole (Sigma) to
block activity of endogenous alkaline phosphatase. All incubations
were carried out at room temperature. Slides were counterstained
with Mayer’s haematoxylin (Sigma) for 2 min. Cells were graded
as negative (–) when no staining was apparent, positive (+) when
staining was clear and unclear (–/+) when staining was difficult to
detect. In all cases, appropriately matched isotype controls and no
antibody controls were used.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
All sequences of PCR primers were as previously reported. RT-
PCR analysis used the following primer sets: mdr-1, 157 bp
product (Bordow et al, 1994), mrp-1, 140 bp product (Bordow et
al, 1994) and lrp, 405 bp product (Stein et al, 1997). All primer
sets spanned an intron to control against amplification of genomic
DNA sequences. All primers were purchased from Oswel DNA
Service Lab (Southampton, UK).
Total RNA (1 mg) was reversed transcribed in a 20 ml volume
using Superscript (GIBCO BRL, Scotland, UK) and random
hexonucleotides (Pharmacia), according to the manufacturer’s
instructions. PCR was performed in a final volume of 25 ml
containing 0.5 mM of each primer, 0.2 mM dNTPs (Pharmacia),
2.5 U ml–1 Taq DNA Polymerase (GIBCO BRL), Taq buffer
(GIBCO BRL) and 1.5–2 mM MgCl2 (GIBCO BRL). An initial
denaturation for 4 min at 94°C was followed by 35 cycles of 30 s
at 94°C, 60 s at 55°C and 60 s at 72°C in an Omnigene thermal
cycler (Hybaid, UK). PCR products were visualized by electro-
phoresis using a 1.5% agarose gel and ethidium bromide staining.
p53 functional analysis
To provide some indication of the p53 functional status, induction
of P53, P21 and MDM2 was measured following irradiation
(O’Connor et al, 1997). Exponentially growing cells were exposed
to 5 Gy irradiation delivered using a 60Co source with a source-to-
flask distance of 40 cm and a dose rate of 1.36 Gy min–1. Cells
were incubated for a further 4 h then harvested for protein extrac-
tion. The protein extracts were immunoblotted as above then
probed for MDM2, P53 and P21. The proteins from irradiated cells
were compared with protein from untreated cells to monitor
changes in these proteins. The samples were also probed for
a-tubulin to ensure even loading.
Growth inhibition assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay (Mosmann, 1983) was used to measure growth
inhibition. Cells were added to each well of a flat bottom 96-well
microtitre plate (Falcon, Becton Dickinson, Cowley, UK) at
concentrations of 2 ´ 103–1  ´ 104 cells per well. The seeding
density was optimized to allow at least three cell doublings during
the assay. The cytotoxic agents doxorubicin, vincristine, cisplatin
and etoposide were added 24 h later. The cells were then incubated
for a further 5 days (7 days for Rh18) after which the number of
viable cells was determined using the MTT assay. Each experi-
mental point was set up in quadruplicate wells and repeated on
three separate occasions. The number of viable cells surviving
drug exposure was expressed as a percentage of the number of
viable cells in the absence of drug. This percentage was then
plotted against drug concentration and from this the IC50 (cytotoxic
dose at which half the cells survive) was obtained.
The method was slightly modified in order to test the effect of
the modulators PSC833 and VX710 on the chemosensitivity of the
cell lines. The effects of the modulators alone were tested using an
MTT assay similar to that outlined above. From this a concentra-
tion of modulator was chosen which killed no more than 10% of
the cells in each cell line. This concentration was 2 mM for both
modulators. The MTT assays were then carried out as above,
except that after 24 h, modulator was added to each well before
addition of the drug. The assay was then continued as normal. On
each plate controls were included and any cytotoxic effects of the
modulators were accounted for in the calculation of IC50. The
ratio of IC50 with and without modulator treatment gives the
sensitization ratio (SR) which was used to compare modulation
between cell lines.Resistance modulation in rhabdomyosarcoma 341
British Journal of Cancer (2000) 83(3), 338–345 © 2000 Cancer Research Campaign
These experiments were carried out using the panel of seven
rhabdomyosarcoma cell lines and also using CH1 and CH1DoxR
as negative and positive controls for modulation.
Vincristine accumulation assay
The accumulation of [3H]-vincristine ([3H]-VCR) was measured in
exponentially growing cells. Cells were exposed to medium
containing 10 nM or 25 nM [3H]-VCR (Amersham, specific
activity 6.2 Ci mmol–1, 0.25 mCi ml–1) and incubated at 37°C for
2 h. To test the effects of modulators on [3H]-VCR accumulation,
cells were incubated with 2 mM modulator 1 h prior to, and during,
[3H]-VCR exposure.
To terminate accumulation of [3H]-VCR, the cells were aspi-
rated dry, washed with PBS at 4°C, and lysed with 2 ml of 1 N
NaOH. Lysis was carried out for 12 h at 37°C then 1.6 ml of lysate
was transferred to a scintillation vial, mixed with 10 ml scintilla-
tion fluid (Ultima Gold, Packard), and counted for tritium in a
liquid scintillation counter (2200CA, Packard). The remaining
0.4 ml was used to determine protein concentration using the
Lowry method (Lowry et al, 1951). From these measurements the
accumulation of [3H]-VCR per mg protein was calculated.
RESULTS
Characterization
Expression of three genes implicated in multidrug resistance (mdr-
1, mrp-1 and lrp) was assayed at both the protein and mRNA level
in the rhabdomyosarcoma cell line panel. Expression of P-gp and
MRP proteins was not detectable in the rhabdomyosarcoma cell
lines by immunoblotting (Figure 1) whereas the control cell lines
gave a strong signal.
Immunohistochemical staining showed that expression of MDR
proteins was undetectable or very low in all of the cell lines except
HX170 which has expression of LRP (Table 2A). In many cases
the staining was barely detectable, as illustrated in Figure 2.
Despite the difficulties in detecting proteins, many of the cell lines
were found to contain mRNA for the resistance genes (Table 2B).
mdr-1, mrp-1 and lrp were found in 5/7, 7/7 and 5/7 cell lines,
respectively. The detection of these is probably due to the high
sensitivity of the PCR assay compared to the protein detection
methods.
The p53 phenotype of the cell line panel was investigated by
measuring levels of P53, P21 and MDM2 4 h following 5 Gy irra-
diation and comparing these to untreated controls (Figure 3). The
a-tubulin levels vary between cell lines but are consistent within
cell-line paired samples, showing that loading was reasonably
accurate. The experiment was repeated twice and the blots
analysed using ImageQuant software.
In the wild-type control, A2780, there is an increase in expres-
sion of MDM2 and P53 leading to a downstream increase in P21,
consistent with the presence of functional p53. Of the rhab-
domyosarcoma cell lines only one, SCMC, appears to be function-
ally wild-type for p53. In HX170 an increase in P21 is seen
following irradiation but there is no corresponding increase in P53
so it is unclear whether p53 is functional. An increase in P21 levels
following irradiation is also seen in RMS, possibly indicating
some p53 function. Rh18 and Rh36 showed overexpression of
MDM2 leading to high levels of P53 and P21 and no response
following irradiation. Both Rh30 and RD had high levels of P53
prior to irradiation and showed no induction of P21, suggesting
mutant p53.
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Figure 1 Typical immunoblots for P-gp and MRP in a panel of human
rhabdomyosarcoma cell lines and control cell lines
Table 2 (A) Expression of MDR-related proteins in rhabdomyosarcoma
lines by immunohistochemistry. (B) Expression of MDR-related genes in
rhabdomyosarcoma lines by RT-PCR. – negative, + positive, –/+ unclear
A
P-gp MRP LRP
Rh18 – –/+ –/+
Rh30 – – –
Rh36 – –/+ –/+
SCMC –/+ – –
HX170 –/+ – +
RMS – – –
RD – –/+ –/+
B
P-gp MRP LRP
Rh18 – + +
Rh30 + + +
Rh36 + + +
SCMC + + –
HX170 + + +
RMS – + –
RD + + +342 HA Cocker et al
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Figure 2 Example immunohistochemistry results. (A) CH1DoxR and (B) RD stained for P-gp using MRK 16, (C) CORL23R and (D) Rh36 stained for MRP
using MRPm6; (E) 2R120 and (F) HX170 stained for LRP using LRP56
MDM-2
P53
P21
-TUB
–     + –     + –     + –     + –     + –     + –     + –     +
A2780 Rh18 Rh30 Rh36 SCMC HX170 RMS RD
Figure 3 Typical immunoblot showing levels of MDM2, P53, P21 and a-tubulin in the rhabdomyosarcoma cell lines and A2780 control. – untreated;
+ 4 h following 5 Gy irradiationResistance modulation in rhabdomyosarcoma 343
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Sensitivity to anti-cancer agents
A growth inhibition assay was used to measure the sensitivity of
the rhabdomyosarcoma cell lines to the commonly used agents
cisplatin, doxorubicin, etoposide and vincristine (Figure 4A–D,
respectively). For cisplatin, the IC50 values range from 0.2–2 mM
and are similar for all the lines including CH1DoxR which over-
expresses P-gp. For doxorubicin, etoposide and vincristine there is
greater variability in the IC50 values although the rhabdomyosar-
coma cell lines are considerably more sensitive than CH1DoxR.
In the rhabdomyosarcoma lines the IC50 values range from
5.4–41.2 nM for doxorubicin, 38–650 nM for etoposide and
0.3–10.3 nM for vincristine.
Overall, there was no clear correlation between drug sensitivity
and p53/mdm2 status, although SCMC, which has wild-type p53
and is derived from a heavily treated patient, was relatively sensi-
tive to the DNA-damaging agents cisplatin, etoposide and doxo-
rubicin. The line HX170 exhibits an interesting pattern of drug
sensitivity as it is most resistant to doxorubicin and etoposide but
relatively sensitive to cisplatin and vincristine.
Modulation of sensitivity
The ability of PSC833 and VX-710 to modulate sensitivity to
cisplatin, doxorubicin, etoposide and vincristine was measured
(Figure 5). A sensitization ratio greater than 1 indicates that modu-
lation is taking place. For cisplatin the sensitization ratios are all
approximately 1 (Figure 5A). This would be expected because
cisplatin is not a substrate for P-gp or MRP. With etoposide
(Figure 5C) some sensitization is seen in HX170, SCMC, RD and
Rh18 but this is low (approximately 2-fold) compared to the sensi-
tization in CH1DoxR (up to 17.8-fold). The amount of sensitiza-
tion seen in CH1DoxR is greatest with doxorubicin and vincristine
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Figure 4 Sensitivity of a panel of human rhabdomyosarcoma cell lines to:
(A) cisplatin, (B) doxorubicin, (C) etoposide and (D) vincristine. IC50 values
given are the mean ± standard deviation from three independent
experiments. CH1DoxR IC50 values not shown; doxorubicin (414±42 nM),
etoposide (2390±710 nM) and vincristine (291±32 nM)
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Figure 5 Modulation of sensitivity of a panel of rhabdomyosarcoma cell
lines to: (A) cisplatin, (B) doxorubicin, (C) etoposide and (D) vincristine using
2 mM PSC833 (open bars) or VX710 (filled bars). Values given are the mean
± standard deviation of three independent experiments. Sensitization ratio
(SR) = IC50 in the absence of modulator/IC50 in the presence of modulator.
Dotted line represents SR = 1 (no sensitization). Values not shown for
CH1DoxR; SR with PSC833 and doxorubicin (53.9 ± 5.5), etoposide
(17.8 ± 2.4), vincristine (455 ± 51); SR with VX710 and doxorubicin
(12.3 ± 2.0), etoposide (1.85 ± 0.07), vincristine (13.4 ± 2.5)
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Figure 6 Accumulation of [3H]-VCR by a panel of rhabdomyosarcoma cell
lines incubated with: (A) 10 nM [3H]-VCR, (B) 25 nM [3H]-VCR in the absence
of modulator (open bars) or with 2 mM PSC833 (closed bars). Values are
mean ± standard deviation from three experiments344 HA Cocker et al
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(Figure 5B and 5D) and is as much as 455-fold. The sensitization
seen in the rhabdomyosarcoma lines is considerably less than this
but is as high as 16-fold in SCMC with vincristine. Sensitization is
also seen at lower levels in HX170 and RD.
The modulator PSC833 is more potent in modulation of VCR
sensitivity in the CH1DoxR ovarian line whereas the modulator
VX710 is significantly more potent in the rhabdomyosarcoma
lines (paired t-test, P < 0.0001).
The sensitization by the modulators is greatest with vincristine
and this may be due to the uptake and efflux mechanisms for this
drug. To investigate this, accumulation of 10 nM and 25 nM [3H]-
VCR was measured both in the presence and absence of PSC833.
PSC833 caused an increase in accumulation in all rhabdomyosar-
coma lines from 1.1-fold in Rh36 to 2.2-fold in SCMC (Figure 6).
Interestingly, the greatest increase was seen in SCMC, but this was
not statistically significant. The accumulation of [3H]-VCR by
CH1DoxR was lower than all the other lines but could be
increased up to 15-fold by addition of PSC833.
DISCUSSION
Rhabdomyosarcoma is an important childhood malignancy where
drug resistance to the major drugs used to treat the disease
(vincristine, etoposide and doxorubicin) limits cure rates. This
study reports the characterization of a panel of human cell lines in
terms of the major proteins which may influence drug response,
chemosensitivity and sensitization by two clinically studied modu-
lators of multidrug resistance.
The rhabdomyosarcoma cell line panel comprises lines derived
from both previously untreated and chemotherapy-treated patients
and displays a wide variety of phenotypes. There are similar
numbers of lines of alveolar and embryonal histology. All of the
lines tested negative for P-gp and MRP by immunoblotting
although it is likely that this technique is not sensitive enough to
identify low levels of the proteins. This is supported by the results
of immunohistochemical staining, which suggests that the level of
proteins is very low and barely detectable, with the exception of
HX170 which expresses LRP.
Consequently, RT-PCR has also been used and shows that the
majority of lines have mdr-1, mrp-1 and lrp mRNA. Similar obser-
vations have also been made in neuroblastoma (Yanagisawa et al,
1999). However, the expression of mRNA does not always reflect
the expression of the protein.
Our studies of the p53 pathway are based on the model that
wild-type p53 induces P21 expression following irradiation and
that therefore induction of P21 is indicative of wild-type p53
(O’Connor et al 1997). However, it should be noted that alternate
mechanisms may also be involved and that our observations
therefore only provide a suggestion of p53 status.
Clinical observations suggest that the function of p53 is often
compromised in paediatric rhabdomyosarcoma (Wurl et al, 1996).
In agreement with this, it is evident from our studies that only one
of the seven rhabdomyosarcoma lines, SCMC, shows P21 induc-
tion following irradiation, suggesting functional p53. Interestingly,
this cell line was relatively sensitive to the DNA-damaging agents
cisplatin, etoposide and doxorubicin, and this is in agreement with
data using the 60 cell-line NCI panel to correlate p53 status and
drug sensitivity (O’Connor et al, 1997). HX170 also shows some
induction of P21 but its status is unclear. Rh30 and RD have
mutations in exons 8 and 7 respectively (Felix et al, 1992; Keleti et
al, 1996). Our results suggest that these mutations lead to a loss of
p53 function, as illustrated by the lack of P21 induction following
irradiation. Two of the lines, Rh18 and Rh36, show overexpression
of MDM2, confirming previously published data (Felix et al,
1992; Keleti et al, 1996). We hypothesize that the overexpression
of MDM2 leads to inactivation of P53 and thus no induction of
P21 following irradiation. Previously published reports have
shown that RMS has a point mutation in the p53 gene (Stratton et
al, 1990). We have observed a slight induction of P21 following
irradiation in this line. We therefore propose that this mutation
may not disable p53 function completely or may be heterozygous.
Neither the presence of MDR proteins nor p53 status of these
lines appeared to correlate with sensitivity to commonly used
chemotherapeutic agents. HX170 showed reduced sensitivity to
cisplatin, doxorubicin and etoposide but not to vincristine, and
SCMC and RD were relatively resistant to vincristine alone.
Interestingly, all three lines are derived from heavily treated
patients and all three lines show some modulation of sensitivity.
Only two of the lines, Rh18 and Rh30, were taken from untreated
patients and neither of these showed any modulation. Four of the
lines from treated patients showed modulation, as high as 16-fold
in SCMC. The level of modulation seen in these lines is relatively
low and therefore it is likely that the MDR proteins present are at
low levels. This may also be more relevant to clinical levels of
expression, where levels of modulation are also low (Cowie et al,
1995).
Sensitization of the rhabdomyosarcoma lines to vincristine was
greater with VX710 than PSC833, in contrast to the P-gp-
expressing ovarian line CH1DoxR. This suggests that the rhab-
domyosarcoma lines may also have low levels of MRP which is
affected by VX710 but to a lesser effect by PSC833 (Germann et
al, 1997b). This is supported by the observation that all the cell
lines express mrp1 mRNA (Table 2).
The ability of the cells to accumulate radiolabelled vincristine
was measured both in the absence and presence of PSC833. In all
cell lines PSC833 increased accumulation of vincristine, regard-
less of MDR phenotype. This implies that there may be low levels
of transport proteins in all the cells which are affected by PSC833.
Alternatively, PSC833 may act via a different mechanism to
increase drug accumulation. One hypothesis is that exposure to
drugs activates a stress response pathway which activates P-gp
and/or  mdr-1 production (Chaudhary and Roninson, 1993).
Therefore the MDR phenotype of the unstressed cell does not
reflect the situation when drugs are added and PSC833 may
interact with the stress response pathway.
In conclusion, the rhabdomyosarcoma cell lines studied do not
show high levels of multidrug resistance. Despite the lack of easily
detectable MDR proteins, there is evidence that the proteins are
present at very low levels. There is also evidence that the sensi-
tivity of the rhabdomyosarcoma lines to drugs, especially
vincristine, can be modulated, by as much as 16-fold in SCMC,
and that accumulation of vincristine can also be increased using
modulators. This may have clinical implications in terms of
excluding P-gp and MRP ‘non-expressors’ from clinical trials of
modulating agents or looking for clear correlations between
expression and modulation benefit. These lines provide a good
model for the development of new strategies in the treatment of
paediatric rhabdomyosarcoma and for elucidating relationships
between protein expression and drug resistance.Resistance modulation in rhabdomyosarcoma 345
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